3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
76
Neoplasm Metastasis
12
Neoplasms
10
Neoplasms by Site
4
Advanced Breast Cancer
4
Squamous Cell Carcinoma of Head and Neck
3
Ovarian Neoplasms
3
Hereditary Sensory and Autonomic Neuropathies
3
Head and Neck Neoplasms
3
Carcinoma, Renal Cell
3
Breast Diseases
3
Recurrence
2
Kidney Neoplasms
2
Endometrial Neoplasms
2
Digestive System Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Advanced Solid Tumors
2
von Hippel-Lindau Disease
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Unilateral Breast Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Skin Diseases
1
Sarcoma, Ewing
1
Sarcoma
1
Interventions
Standard of Care
2
COVID-19 Vaccines
2
regorafenib
1
proxalutamide
1
palbociclib
1
cilgavimab and tixagevimab drug combination
1
bemcentinib
1
acalabrutinib
1
Sorafenib
1
Sodium Chloride
1
Rabeprazole
1
NVX-CoV2373 adjuvated lipid nanoparticle
1
Janus Kinase Inhibitors
1
Interleukin-7
1
IBIO123
1
Gelsolin
1
COH04S1 COVID-19 vaccine
1
3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
1
2019-nCoV Vaccine mRNA-1273
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
1-palmityl-2-(4-carboxybutyl)-sn-glycero-3-phosphocholine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
COVID-19
×
palbociclib
×
Clear all
NCT05371275
2022-11-07
CDK6COV
biotx.ai GmbH
Phase 2
Withdrawn